Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialSamir K. Gupta, Ellen Koenig, Moti Ramgopal et al.|The Lancet HIV|2022Cited by 107
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trialOnyema Ogbuagu, Hui Wang, Nicolas Margot et al.|The Lancet HIV|2023Cited by 71
In Vitro Suppression of Soilborne Plant Pathogens by CoirNaveen Hyder, Stephen N. Wegulo, James J. Sims|HortTechnology|2009Cited by 5